536 related articles for article (PubMed ID: 18083509)
1. Pathogenic autoantibodies in systemic sclerosis.
Gabrielli A; Svegliati S; Moroncini G; Avvedimento EV
Curr Opin Immunol; 2007 Dec; 19(6):640-5. PubMed ID: 18083509
[TBL] [Abstract][Full Text] [Related]
2. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets.
Gabrielli A; Svegliati S; Moroncini G; Luchetti M; Tonnini C; Avvedimento EV
Autoimmun Rev; 2007 Dec; 7(2):121-6. PubMed ID: 18035321
[TBL] [Abstract][Full Text] [Related]
3. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis.
Baroni SS; Santillo M; Bevilacqua F; Luchetti M; Spadoni T; Mancini M; Fraticelli P; Sambo P; Funaro A; Kazlauskas A; Avvedimento EV; Gabrielli A
N Engl J Med; 2006 Jun; 354(25):2667-76. PubMed ID: 16790699
[TBL] [Abstract][Full Text] [Related]
4. Anti-topoisomerase I autoantibodies in systemic sclerosis.
Czömpöly T; Simon D; Czirják L; Németh P
Autoimmun Rev; 2009 Jul; 8(8):692-6. PubMed ID: 19393194
[TBL] [Abstract][Full Text] [Related]
5. Functional autoantibodies in systemic sclerosis pathogenesis.
Kill A; Riemekasten G
Curr Rheumatol Rep; 2015 May; 17(5):34. PubMed ID: 25876754
[TBL] [Abstract][Full Text] [Related]
6. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
Hénault J; Tremblay M; Clément I; Raymond Y; Senécal JL
Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
[TBL] [Abstract][Full Text] [Related]
7. [Immunopathological disturbances in systemic sclerosis].
Gindzieńska-Sieśkiewicz E; Klimiuk PA; Kowal-Bielecka O; Sierakowski S
Pol Merkur Lekarski; 2005 Dec; 19(114):800-3. PubMed ID: 16521427
[TBL] [Abstract][Full Text] [Related]
8. Update on autoantibodies in systemic sclerosis.
Walker JG; Fritzler MJ
Curr Opin Rheumatol; 2007 Nov; 19(6):580-91. PubMed ID: 17917539
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies against the platelet-derived growth factor receptor in scleroderma: comment on the articles by Classen et al and Loizos et al.
Gabrielli A; Moroncini G; Svegliati S; Avvedimento EV
Arthritis Rheum; 2009 Nov; 60(11):3521-2. PubMed ID: 19877075
[No Abstract] [Full Text] [Related]
10. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.
Grassegger A; Pohla-Gubo G; Frauscher M; Hintner H
Wien Med Wochenschr; 2008; 158(1-2):19-28. PubMed ID: 18286246
[TBL] [Abstract][Full Text] [Related]
11. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells.
Lunardi C; Bason C; Navone R; Millo E; Damonte G; Corrocher R; Puccetti A
Nat Med; 2000 Oct; 6(10):1183-6. PubMed ID: 11017152
[TBL] [Abstract][Full Text] [Related]
12. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis.
Kim D; Peck A; Santer D; Patole P; Schwartz SM; Molitor JA; Arnett FC; Elkon KB
Arthritis Rheum; 2008 Jul; 58(7):2163-73. PubMed ID: 18576347
[TBL] [Abstract][Full Text] [Related]
13. Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab.
Fraticelli P; De Vita S; Franzolini N; Svegliati S; Scott CA; Tonnini C; Spadoni T; Gabrielli B; Pomponio G; Moroncini G; Gabrielli A
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S160-7. PubMed ID: 26339895
[TBL] [Abstract][Full Text] [Related]
14. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Takehara K; Tedder TF
Mol Immunol; 2004 Nov; 41(12):1123-33. PubMed ID: 15482848
[TBL] [Abstract][Full Text] [Related]
15. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.
Komura K; Fujimoto M; Yanaba K; Matsushita T; Matsushita Y; Horikawa M; Ogawa F; Shimizu K; Hasegawa M; Takehara K; Sato S
Ann Rheum Dis; 2008 Jun; 67(6):867-72. PubMed ID: 17823201
[TBL] [Abstract][Full Text] [Related]
16. Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.
Patterson KA; Roberts-Thomson PJ; Lester S; Tan JA; Hakendorf P; Rischmueller M; Zochling J; Sahhar J; Nash P; Roddy J; Hill C; Nikpour M; Stevens W; Proudman SM; Walker JG
Arthritis Rheumatol; 2015 Dec; 67(12):3234-44. PubMed ID: 26246178
[TBL] [Abstract][Full Text] [Related]
17. Anti-endothelial cell antibodies in systemic sclerosis.
Mihai C; Tervaert JW
Ann Rheum Dis; 2010 Feb; 69(2):319-24. PubMed ID: 20107031
[TBL] [Abstract][Full Text] [Related]
18. DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients.
Hénault J; Robitaille G; Senécal JL; Raymond Y
Arthritis Rheum; 2006 Mar; 54(3):963-73. PubMed ID: 16508979
[TBL] [Abstract][Full Text] [Related]
19. Stimulatory autoantibodies to the PDGF receptor in scleroderma.
Okamoto H
N Engl J Med; 2006 Sep; 355(12):1278; author reply 1279. PubMed ID: 16998964
[No Abstract] [Full Text] [Related]
20. [Systemic sclerosis autoantibodies: what dermatologists must know].
Hüe S; Ingen-Housz-Oro S; Cosnes A
Ann Dermatol Venereol; 2013 Feb; 140(2):143-9. PubMed ID: 23395500
[No Abstract] [Full Text] [Related]
[Next] [New Search]
